---
schema_version: "secwatch.filing_event.v1"
accession: "0001503274-25-000022"
form_type: "8-K"
ticker: "QTRX"
cik: "0001503274"
company_name: "Quanterix Corp"
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T17:31:54.574735+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Quanterix highlights Akoya acquisition benefits; responds to Kent Lake director nominations

## Summary
- Acquisition unlocks $5B addressable market in spatial biology and $10B Alzheimer's diagnostics opportunity.
- Expects ~$40M annual run-rate cost synergies by end of 2026, with $20M in the first year after close.
- Targets ~$1B revenue and ~15% EBIT margins within five years post-close; positive free cash flow expected in 2026.
- Kent Lake PR LLC nominated three director candidates for 2025 Annual Meeting; Quanterix criticizes assumptions as flawed.
- Transaction expected to close in Q2 2025, pending shareholder approvals and customary conditions.

## SEC filing metadata
- accession: 0001503274-25-000022
- form_type: 8-K
- ticker: QTRX
- cik: 0001503274
- company_name: Quanterix Corp
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503274/000150327425000022/0001503274-25-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503274/000150327425000022/qtrx-20250303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001503274-25-000022
- JSON: https://secwatch.observer/filing/0001503274-25-000022.json
- Plain text: https://secwatch.observer/filing/0001503274-25-000022.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.